Literature DB >> 33505511

The Antitumour Effect of Prunella vulgaris Extract on Thyroid Cancer Cells In Vitro and In Vivo.

Fangqin Yu1,2, Lele Zhang1,2, Runsheng Ma1,2, Chenguang Liu1,2, Qingduan Wang3, Detao Yin1,2.   

Abstract

Prunella vulgaris, a traditional Chinese medicine, has been used to treat various benign and malignant tumours for centuries in China. In our previous studies, Prunella vulgaris extract (PVE) was shown to promote apoptosis in differentiated thyroid cancer (DTC) cells. However, whether other mechanisms are involved in the antitumour effect of PVE in thyroid cancer (TC) cells remains unclear. The present study aimed to investigate the antiproliferative and antimigratory effects of PVE on TC cell lines both in vitro and in vivo. First, the TPC-1 and SW579 human TC cell lines were screened by MTT assay for their high level of sensitivity to PVE. Then, the results of cell growth curve and colony formation assay and cell cycle analyses, wound healing, and migration assays demonstrated that PVE inhibited the proliferation and migration of TPC-1 and SW579 cells. Moreover, the antitumour effect of PVE was verified in a subcutaneous xenotransplanted tumour model. Next, MKI67, PCNA, CTNNB1, and CDH1 were screened by qRT-PCR for their significantly differential expression levels in xenograft tissue with and without PVE treatment, and expression of MKI67, PCNA, and CDH1 was verified by Western blot. Finally, an integrated bioinformatics analysis containing protein-protein interaction network, KEGG pathway, and GO analysis was conducted to explore more potential antitumour mechanisms of PVE. In summary, PVE could inhibit the proliferation and migration of TC cells both in vitro and in vivo, which may have been achieved by modulation of the expression of MKI67, PCNA, and CDH1. These data suggest that PVE has the potential to be developed into a new anticancer drug for the treatment of TC.
Copyright © 2021 Fangqin Yu et al.

Entities:  

Year:  2021        PMID: 33505511      PMCID: PMC7811421          DOI: 10.1155/2021/8869323

Source DB:  PubMed          Journal:  Evid Based Complement Alternat Med        ISSN: 1741-427X            Impact factor:   2.629


  32 in total

Review 1.  Thyroid Hormone Suppression Therapy.

Authors:  Bernadette Biondi; David S Cooper
Journal:  Endocrinol Metab Clin North Am       Date:  2018-12-04       Impact factor: 4.741

2.  Clinical outcomes of patients with papillary thyroid carcinoma after the detection of distant recurrence.

Authors:  Yasuhiro Ito; Takuya Higashiyama; Yuuki Takamura; Kaoru Kobayashi; Akihiro Miya; Akira Miyauchi
Journal:  World J Surg       Date:  2010-10       Impact factor: 3.352

3.  Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.

Authors:  Leslie Wilson; Wei Huang; Linda Chen; Jie Ting; Vicky Cao
Journal:  Thyroid       Date:  2017-06-07       Impact factor: 6.568

Review 4.  Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review.

Authors:  Roger T Anderson; John E Linnehan; Vanita Tongbram; Karen Keating; Lori J Wirth
Journal:  Thyroid       Date:  2013-04       Impact factor: 6.568

Review 5.  Prunella vulgaris: A Comprehensive Review of Chemical Constituents, Pharmacological Effects and Clinical Applications.

Authors:  Su-Juan Wang; Xiao-He Wang; Yuan-Yuan Dai; Ming-Hua Ma; Khalid Rahman; Hua Nian; Hong Zhang
Journal:  Curr Pharm Des       Date:  2019       Impact factor: 3.116

6.  A polysaccharide fraction from medicinal herb Prunella vulgaris downregulates the expression of herpes simplex virus antigen in Vero cells.

Authors:  Lawrence Chi-Ming Chiu; Wen Zhu; Vincent Eng-Choon Ooi
Journal:  J Ethnopharmacol       Date:  2004-07       Impact factor: 4.360

7.  The Chinese herb Prunella vulgaris promotes apoptosis in human well-differentiated thyroid carcinoma cells via the B-cell lymphoma-2/Bcl-2-associated X protein/caspase-3 signaling pathway.

Authors:  De-Tao Yin; Mengyuan Lei; Jianhui Xu; Hongqiang Li; Yongfei Wang; Zhen Liu; Runsheng Ma; Kun Yu; Xianghua Li
Journal:  Oncol Lett       Date:  2017-06-06       Impact factor: 2.967

8.  Oral Administration of Prunella vulgaris L Improves the Effect of Taxane on Preventing the Progression of Breast Cancer and Reduces Its Side Effects.

Authors:  Jixue Zhao; Degang Ji; Xujie Zhai; Lirong Zhang; Xiao Luo; Xin Fu
Journal:  Front Pharmacol       Date:  2018-08-03       Impact factor: 5.810

9.  PFKFB2 Promoter Hypomethylation as Recurrence Predictive Marker in Well-Differentiated Thyroid Carcinomas.

Authors:  Mateus Camargo Barros-Filho; Larissa Barreto Menezes de Lima; Mariana Bisarro Dos Reis; Julia Bette Homem de Mello; Caroline Moraes Beltrami; Clóvis Antonio Lopes Pinto; Luiz Paulo Kowalski; Silvia Regina Rogatto
Journal:  Int J Mol Sci       Date:  2019-03-16       Impact factor: 5.923

10.  Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection.

Authors:  Xu Zhang; Zhujun Ao; Alexander Bello; Xiaozhuo Ran; Shuiping Liu; Jeffrey Wigle; Gary Kobinger; Xiaojian Yao
Journal:  Antiviral Res       Date:  2016-01-09       Impact factor: 5.970

View more
  3 in total

Review 1.  Phytochemistry, Pharmacology and Quality Control of Xiasangju: A Traditional Chinese Medicine Formula.

Authors:  Siyuan Wu; Hua Luo; Zhangfeng Zhong; Yongjian Ai; Yonghua Zhao; Qionglin Liang; Yitao Wang
Journal:  Front Pharmacol       Date:  2022-06-23       Impact factor: 5.988

2.  Upregulated SLC27A2/FATP2 in differentiated thyroid carcinoma promotes tumor proliferation and migration.

Authors:  Kaixiang Feng; Runsheng Ma; Hongqiang Li; Keyu Yin; Gongbo Du; Xin Chen; Zhen Liu; Detao Yin
Journal:  J Clin Lab Anal       Date:  2021-12-02       Impact factor: 2.352

3.  Water-Extracted Prunella vulgaris Alleviates Endometriosis by Reducing Aerobic Glycolysis.

Authors:  Min Kyoung Cho; Ling Jin; Jung Ho Han; Jung-Suk Jin; Se-Yun Cheon; Su Shin; Sung-Jin Bae; Jang-Kyung Park; Ki-Tae Ha
Journal:  Front Pharmacol       Date:  2022-04-04       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.